Close Menu

NEW YORK (GenomeWeb) – Biodesix today announced that UnitedHealthcare has issued a positive coverage decision for the VeriStrat test for advanced non-small cell lung cancer. 

UnitedHealthcare covers 44.7 million lives in the US. 

VeriStrat is a blood-based proteomic test that provides prognostic and predictive data to help guide treatment of patients with advanced NSCLC. Those with VeriStrat Poor test results have a shorter medical overall survival that those with VeriStrat Good results, Boulder, Colorado-based Biodesix said. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.

The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.

A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.

In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.